You are here

Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Kinki University Hospital
Osakasayama, Osaka, 589-8511 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients treated with Torisel (patients with metastatic and/or radically unresectable
or advanced renal cell carcinoma).

- Among patients registered and treated in the Special Investigation, All-case Survey of
Torisel, those continuously treated with Torisel for more than 24 weeks will be
included.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients not administered Torisel.

- Patients with a history of severe hypersensitivity to temsirolimus, sirolimus
derivative, or any of their components and/or derivatives.

NCT01420601
Pfizer
Completed
Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now